Medpace Holdings Inc

Research Medpace Holdings Inc (MEDP) on Bullrun: valuation model: 1.5% overvalued, market cap USD 15.27B, P/E 33.6. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerMEDP
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryDiagnostics & Research
• CurrencyUSD
• Valuation signal1.5% overvalued
• Market capUSD 15.27B
• P/E33.6
• Financial periodFY2025
• RevenueUSD 2.53B
• Revenue growth20.0%
• Net incomeUSD 451.12M
• Free cash flowUSD 681.87M

Valuation Snapshot

Bullrun's latest valuation model marks Medpace Holdings Inc as 1.5% overvalued; latest market cap is USD 15.27B; P/E is 33.6.

About Medpace Holdings Inc

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries;

Frequently asked questions

Is Medpace Holdings Inc overvalued or undervalued?

Bullrun's valuation model currently marks Medpace Holdings Inc as 1.5% overvalued.

What is Medpace Holdings Inc's market cap?

Medpace Holdings Inc's market capitalization is USD 15.27B.

What is Medpace Holdings Inc's P/E ratio?

Medpace Holdings Inc's price-to-earnings (P/E) ratio is 33.6.

What does Medpace Holdings Inc do?

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.